Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda -7/IL-24–mediated toxicity
Male
0301 basic medicine
Interleukins
Gossypol
Mice, Nude
Prostatic Neoplasms
Apoptosis
Genetic Therapy
Transfection
Xenograft Model Antitumor Assays
3. Good health
Mice
03 medical and health sciences
Proto-Oncogene Proteins c-bcl-2
Cell Line, Tumor
Antineoplastic Combined Chemotherapy Protocols
Animals
Humans
Myeloid Cell Leukemia Sequence 1 Protein
DOI:
10.1073/pnas.1100769108
Publication Date:
2011-05-10T06:10:02Z
AUTHORS (19)
ABSTRACT
Limited options are available for treating patients with advanced prostate cancer (PC). Melanoma differentiation associated gene-7/interleukin-24 ( mda -7/IL-24), an IL-10 family cytokine, exhibits pleiotropic anticancer activities without adversely affecting normal cells. We previously demonstrated that suppression of the prosurvival Bcl-2 member, myeloid cell leukemia-1 (Mcl-1), is required -7/IL-24–mediated apoptosis carcinomas. Here we demonstrate pharmacological inhibition Mcl-1 expression unique Apogossypol derivative BI-97C1, also called Sabutoclax, sufficient to sensitize tumors -7/IL-24–induced apoptosis, whereas ABT-737, which lacks efficacy in inhibiting Mcl-1, does not cytotoxicity. A combination regimen tropism-modified adenovirus delivered -7/IL-24 (Ad.5/3- -7) and BI-97C1 enhances cytotoxicity human PC cells, including those resistant or alone. The causes autophagy facilitates NOXA- Bim-induced Bak/Bax-mediated mitochondrial apoptosis. Treatment Ad.5/3- -7 significantly inhibits growth xenografts nude mice spontaneously induced Hi-myc transgenic mice. Tumor correlated increased TUNEL staining decreased Ki-67 both prostates These findings derivative, sensitizes PCs cytotoxicity, thus potentially augmenting therapeutic benefit this combinatorial approach toward PC.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (25)
CITATIONS (107)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....